The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
LDL Cholesterol

This site was built with web standards. You are currently viewing the unformatted version of the website. Please update your browser in order to view the site.

Internet Explorer 5 or greater
Netscape 7
Mozilla
Opera 6 or greater

INDICATIONS

VYTORIN is indicated as adjunctive therapy to diet for the reduction of elevated TOTAL-C, LDL-C, Apo B, TG, and non–HDL-C, and to increase HDL-C in patients with primary (heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia when diet alone is not enough.

CONTRAINDICATIONS

Hypersensitivity to any component of this medication; active liver disease; unexplained persistent elevations of serum transaminases; and women who are pregnant, nursing, or may become pregnant.

VYTORIN contains 2 active ingredients: ezetimibe and simvastatin. No incremental benefit of VYTORIN on cardiovascular morbidity and mortality over and above that demonstrated for simvastatin has been established.

The clinical impact of comparative differences in lipid changes between products is not known.

Click here for Selected Cautionary Information.

Reference:
1.
IMS HEALTH, NPA Plus™, NRx, July 2006.
This site is intended only for health care professionals of the United States, its territories, and Puerto Rico.
For non-US Health care Professionals, click here.

VYTORIN and ZETIA are registered trademarks of MSP Singapore Company, LLC.

Other brands listed are the trademarks of their respective owners and are not trademarks of MSP Singapore Company, LLC.

Merck/Schering-Plough Pharmaceuticals
20850431(1)-03/08-VYT